找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Dose Finding and Beyond in Biopharmaceutical Development; Jingjing Ye,Ding-Geng Chen,Joseph C. Cappelleri Book 2025 The Editor(s) (if appl

[復(fù)制鏈接]
樓主: EVOKE
21#
發(fā)表于 2025-3-25 05:42:45 | 只看該作者
Dose Optimization of Oncology Drugs: A Clinical and Regulatory Perspectiveluding leukemia 2023, kidney cancer, and melanoma (Siegel, CA Cancer J Clin 73(1):17–48, 2023). The development of targeted therapies, in particular, has dramatically altered the therapeutic landscape and improved outcomes for patients. Despite the seismic changes that have occurred in the field, so
22#
發(fā)表于 2025-3-25 10:15:56 | 只看該作者
23#
發(fā)表于 2025-3-25 14:22:44 | 只看該作者
Novel Oncology Dose-Finding Designs for the New Millenniume treatments, oncology trials need to start human research at a lower dose level and then move up and down through some dose levels in a process called dose finding that helps determine a safe dose level. The toxicity of these oncology drugs is always assumed to increase with dose. However, unlike i
24#
發(fā)表于 2025-3-25 16:56:48 | 只看該作者
Practical Guidance on Oncology Dose Escalation Designshe dose limiting toxicity (DLT) data have been widely implemented in real clinical trials, including rule-based designs (e.g., i3+3), model-based designs (e.g., CRM and BLRM) and model-assisted designs (e.g., mTPI, mTPI-2, and BOIN). In this chapter, we have a brief review of popular novel designs,
25#
發(fā)表于 2025-3-25 21:20:55 | 只看該作者
Monotonic Dose–Response and Curve-Free Designs for Phase I Dose-Finding Trialsed designs typically use parametric models to facilitate the exchange of information across dose levels, curve-free designs rely solely on the monotonic assumption to extrapolate data between doses. In the first part of this chapter, we present several curve-free designs for phase I trials that were
26#
發(fā)表于 2025-3-26 02:36:42 | 只看該作者
27#
發(fā)表于 2025-3-26 06:04:40 | 只看該作者
28#
發(fā)表于 2025-3-26 12:25:31 | 只看該作者
29#
發(fā)表于 2025-3-26 16:03:22 | 只看該作者
Patient-Reported Tolerability in Oncology Drug DevelopmentThere is a growing understanding of and encouragement for the use of PROs to capture tolerability. Traditionally, tolerability has been defined as the absence of serious adverse events. More recent and patient-centric definitions of tolerability have been put forward, focusing on how patients feel a
30#
發(fā)表于 2025-3-26 17:21:51 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-26 00:09
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
云霄县| 台州市| 武乡县| 沧州市| 安宁市| 淳化县| 马鞍山市| 朔州市| 青河县| 加查县| 巴楚县| 鄂伦春自治旗| 炉霍县| 昌都县| 大邑县| 南召县| 红安县| 桐城市| 综艺| 元阳县| 庄浪县| 蓬安县| 太白县| 南郑县| 余庆县| 镶黄旗| 乃东县| 江山市| 四会市| 大城县| 镇平县| 房山区| 建昌县| 大方县| 固安县| 兴化市| 盐亭县| 阿克陶县| 岢岚县| 海阳市| 沛县|